Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.
Saved in:
| Title: | Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria. |
|---|---|
| Authors: | Ji Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Calonder C; Novartis BioMedical Research, Basel, Switzerland., Kirsiläe T; Novartis Pharma AG, Basel, Switzerland., Burciu A; Novartis Pharma AG, Basel, Switzerland., Laurent N; Novartis BioMedical Research, Basel, Switzerland., Hua E; China Novartis Biomedical Research Co. Ltd, Shanghai, China., Severin T; Novartis Pharma AG, Basel, Switzerland., Patekar M; Novartis Pharma AG, Basel, Switzerland., Woessner R; Novartis BioMedical Research, Basel, Switzerland. |
| Source: | Clinical and translational science [Clin Transl Sci] 2026 Jul; Vol. 19 (7), pp. e70661. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1752-8062 |
|---|---|
| DOI: | 10.1111/cts.70661 |
